Experimental approaches: dietary and hormone therapy.
Patients who suffer from intestinal failure depend on parenteral support to maintain nutritional equilibrium. In this chapter, recommendations for evaluation the absorptive capacity of patients with intestinal failure are defined, and the evidence and magnitude of the effect of dietary and hormone therapy is given. Regarding dietary advice, the effects of employment of diets with various carbohydrate:fat ratios in short-bowel syndrome (SBS) patients with and without a preserved colon is presented. Focus has been placed on the use of growth hormone but also on the use of a novel intestinotrophic hormone, glucagon-like peptide 2, in the promotion of intestinal adaptation in SBS patients. Overall, the ultimate aim in the treatment of SBS patients is to optimize remnant intestinal function, thereby eliminating the need for parenteral support and improving quality of life in these patients.
Jeppesen
P B
PB
Department of Medicine CA-2121, Section of Gastroenterology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100, Copenhagen, Denmark. bekker@dadlnet.dk
Mortensen
P B
PB
D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D053767:Glucagon-Like Peptide 2; D004763:Glucagon-Like Peptides; D013006:Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D007408:Intestinal Absorption; D007582:Jejunostomy; D010446:Peptide Fragments / Q000008:administration & dosage*; D012778:Short Bowel Syndrome / Q000178:diet therapy* / Q000188:drug therapy* / Q000378:metabolism
D005765:Gastrointestinal Agents; D053767:Glucagon-Like Peptide 2; D010446:Peptide Fragments; D004763:Glucagon-Like Peptides; D013006:Growth Hormone